BlackRock Inc. Purchases Shares of 1,474,769 Sionna Therapeutics, Inc. $SION

Key Points

• BlackRock acquired 1,474,769 Sionna Therapeutics shares worth approximately $64.9 million, giving it a 3.27% stake. Other institutional investors, including UBS and Vanguard, also increased or initiated positions.
• SION shares opened at $5.87, far below their 12-month high of $54.97. The company reported a quarterly loss of $0.66 per share, missing analysts’ estimate of a $0.64 loss.
• Analyst sentiment has weakened, with several firms downgrading the stock to “Hold” or “Market Perform.” The consensus rating is “Hold”, with a target price of $42.22, while insiders have sold more than $18.25 million of shares over the past three months.

BlackRock Inc. acquired a new position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,474,769 shares of the company's stock, valued at approximately $64,875,000. BlackRock Inc. owned approximately 3.27% of Sionna Therapeutics at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in SION. UBS Group AG raised its stake in shares of Sionna Therapeutics by 91.1% in the fourth quarter. UBS Group AG now owns 89,177 shares of the company's stock valued at $3,669,000 after acquiring an additional 42,511 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Sionna Therapeutics by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company's stock valued at $48,749,000 after acquiring an additional 41,797 shares during the last quarter. Candriam S.C.A. acquired a new stake in Sionna Therapeutics in the first quarter worth about $9,494,000. Eventide Asset Management LLC bought a new stake in Sionna Therapeutics during the 4th quarter worth about $26,290,000. Finally, Seven Grand Managers LLC acquired a new position in Sionna Therapeutics in the fourth quarter valued at approximately $2,057,000.

Sionna Therapeutics Stock Performance

Shares of SION opened at $5.87 on Monday. The stock has a market capitalization of $265.38 million, a PE ratio of -2.69 and a beta of 1.32. The firm's 50 day moving average is $33.25 and its 200-day moving average is $36.70. Sionna Therapeutics, Inc. has a 12 month low of $4.01 and a 12 month high of $54.97.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). Equities research analysts predict that Sionna Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SION has been the subject of a number of analyst reports. Raymond James Financial cut shares of Sionna Therapeutics from a "strong-buy" rating to a "market perform" rating in a report on Monday, August 10th. JonesTrading downgraded Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 10th. Citizens Jmp downgraded Sionna Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, August 10th. Freedom Capital cut shares of Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 20th. Finally, Lifesci Capital cut Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 10th. One investment analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Sionna Therapeutics has a consensus rating of "Hold" and a consensus target price of $42.22.

Insider Buying and Selling at Sionna Therapeutics

In related news, Director Orbimed Advisors Llc sold 85,918 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the business's stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. This trade represents a 3.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 403,524 shares of company stock worth $18,250,367. 5.10% of the stock is currently owned by company insiders.

Sionna Therapeutics Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source